UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence, announced today that Dan Rose has been appointed as the new chairman of its board.
UroMem's co-founder and CEO Hamid Lamraoui said he was very pleased to welcome Dan as the new board chair.
Rose brings more than 25 years of medical device experience to the UroMems board.
Rose said that he was grateful to have the opportunity to move into this role and that he was impressed by the strong momentum UroMems has built up so far.
UroMems has achieved critical milestones in research and development, clinical outcomes and building the organization, including recently securing $47 million in funding on the heels of exceptional results from the first-in-human multicenter clinical studies.
40 million Americans and 90 million Europeans are affected by SUI.
The UroMems technology platform is protected by more than 150 granted patents and is designed to overcome the limitations of current solutions.
You can find more information at www.uromems.com.
Email protected,Shelli is the media contact.
The source is UroMems.
The first smart automated implant to treat stress urinary incontinence is being developed by UroMems.
UroActive®, le premier implant automatisé intelligent pour le traitement de l'ontinence urinaire, is a medtech internationale.
Do not sell or share my information.

Source prnewswire